Please use this identifier to cite or link to this item:
Title: An investigation of Clostridium species present in nutraceutical preparations of Arthrospira platensis (Spirulina) for human consumption
Authors: Hoekstra, Dirk T 
Volschenk, Heinrich 
Collins, Michelle 
McMaster, Lynn. D 
Keywords: Arthrospira (Spirulina) platensis Clostridium Anaerobes;Health supplements;Immunocompromised;Nutraceuticals
Issue Date: 2011
Publisher: Springer
Source: Hoekstra, D.T., Volschenk, H., Collins, M. et al. J Appl Phycol (2011) 23: 777. doi:10.1007/s10811-010-9630-7
Abstract: The presence of the anaerobic spore former Clostridium in Arthrospira platensis destined for human consumption is generally not assessed during quality assurance procedures. As this nutraceutical is administered as complementary medicine to the immunocompromised, this study aimed to investigate the presence of these potential pathogens. Anaerobic counts performed on tablets from a single manufacturer indicated an excess of 105 CFU/endospores g−1 tablet for three different A. platensis batches. Tests for coliforms for use as “indicators” of pathogens in the tablets were negative. Using classic culture techniques, five species of Clostridium were isolated. Subsequent use of PCR-denaturing gradient gel electrophoresis (DGGE) fingerprinting of tablets showed a divergent microbial population, with a predominance of anaerobic endospore formers, including Clostridium. Sequencing of a 1.5 kb 16S rDNA clone library and phylogenetic analyses of prominent operational taxonomic units confirmed the presence of an additional five Clostridium spp. and other genera in the tablets. A composite molecular ladder, using 16S rRNA DGGE amplicons of 17 representative bacterial species was constructed to assist in identifying anaerobes present in tablets sourced from three different A. platensis manufacturers. Results indicated that commercial A. platensis preparations were contaminated with potentially hazardous clostridia and other anaerobic species. Results suggest that certain commercial A. platensis preparations require stringent microbial quality assurance measures to ensure safe use as a nutraceutical for the immunocompromised and the general public.
Appears in Collections:Appsc - Journal Articles (DHET subsidised)

Files in This Item:
File Description SizeFormat 
Hoekstra_DT_Volschenk_H_Collins_M_McMaster_LD_AppSci_2011.pdfMain Article546.97 kBAdobe PDFView/Open
Show full item record

Page view(s)

Last Week
Last month
checked on May 24, 2019


checked on May 24, 2019

Google ScholarTM


This item is licensed under a Creative Commons License Creative Commons